Abstract
Sizofiran is a polysaccharide which is known to be an immunopotentiating agent with anti-tumor effects. We had administered 20-40 mgs of Sizofiran per week, intramuscularly, to nine patients with head and neck malignancies. In addition, the standard treatment with irradiation, chemotherapy, and surgery was carrded out. Comparisons between the Sizofiran-treated group and a similar group, not treated with sizofiran, as a control, were made. Clinical symptoms, and white blood cell (WBC) and lymphocyte counts were evaluated. Both groups showed good clinical prognoses. In the control group, as treatment progressed, the decrease in WBC and lymphocyte counts became obvious. This decrease continued during the treatment period. By comparison, the Sizofiran group showed no decrease in WBC and lymphocyte counts for the same period. These results indicate the effectiveness of Sizofiran in immunotherapy of patients with head and neck malignancies.
